In autologous and allogeneic hematopoietic SCT (HSCT) neutropenia may be associated with severe infection. Immunodeficiency associated with GVHD and its treatment in allogeneic HSCT is also a risk for severe infection. In both periods, patients may develop severe sepsis with organ failure. To gain insights into treatment possibilities, HISTORY, a multicenter retrospective study reviewed HSCT patient records on mortality, organ dysfunction, platelet count and bleeding events. All transplantation records from 16 European centers were reviewed for 1.5 years. Of 2092 patients screened, 160 were documented for HSCT with respiratory and/or cardiovascular organ dysfunction because of sepsis and/or GVHD. Mortality was 53.1% at 28 days and 65.6% at 100 days. HSCT patients with sepsis and organ dysfunction are at highest risk of death (49.5%). Death from refractory septic shock was 15.2%, and it was 20% from respiratory failure and 64.7% from sepsis. Fewer than 3% of HSCT patients died from bleeding complications; however, individuals at increased risk of bleeding were excluded. Despite low platelet counts, an increased risk of bleeding could be established only if thrombocytopenia dropped below 13 Â 10 9 /l. Thus, there might be a therapeutic window for treatment strategies for severe sepsis in HSCT, such as drotrecogin alfa (activated).
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Introduction
Frequent and well-known complications of hematopoietic SCT (HSCT) are infection, GVHD and regimen-related toxicity, often connected with organ dysfunctions. Both autologous and allogeneic SCTs are accompanied by a period of neutropenia before engraftment, in which the incidence of infection is high. In addition, acute and late acute GVHD and its treatment result in a prolonged immunodeficiency associated with a significant additional risk of severe infections. Dysregulated inflammatory pathways such as endothelial and monocyte activation may contribute to the severity of sepsis. 1 In acute and late acute GVHD, patients who develop sepsis associated with cardiovascular and respiratory failure in concomitance with other severe complications and organ dysfunctions generally have poor outcomes. Mortality rates range from 39 to 490%. 2 A strong independent predictor of poor outcome appears to be mechanical ventilation in allogeneic transplant recipients, with survival rates less than 20%. 1, 3, 4 Thus sepsis and GVHD are major causes of morbidity and mortality in HSCT patients, and may have common pathophysiological pathways explaining severe clinical courses.
Drotrecogin alfa (activated) (DAA), a recombinant form of human activated protein C, is approved in the EU for treatment of severe sepsis in adults with multiple organ dysfunction. In 2001, the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PRO-WESS) trial showed that a 96-h i.v. infusion (24 mg/kg/h) of DAA caused a relative mortality risk reduction at 28 days of 19.4% (95% confidence interval (CI) 6.6-30.5), with an absolute mortality reduction of 6.1% (95% CI 1.9-10.4). 5 An increased rate of serious bleeding events among patients treated with DAA compared with placebo is reported both in the product's summary of product characteristics and in the literature (2.4 vs 1.0% during infusion of study drug/ placebo and 3.5 vs 2.0% over the 28-day study period in PROWESS). SCT patients were excluded in PROWESS to avoid any increased risk of bleeding.
Nevertheless, for HSCT patients who develop organ dysfunction in association with sepsis or GVHD, the mortality is high, and pathophysiological considerations might justify treatments such as DAA use to improve survival in these patients.
A multicenter retrospective review of HSCT patient records, HISTORY, was conducted to evaluate the natural history, that is, incidence of bleeding events and mortality rates, and to better understand the relationship between mortality, organ dysfunction, platelet count, and bleeding events in HSCT patients who experienced respiratory and/or cardiovascular organ dysfunction because of severe sepsis and/or GVHD.
This study aimed to gather a comprehensive documentation on the criteria detailed above, in a representative, predefined population of HSCT patients, to generate a basis for the design of a clinical trial with DAA in HSCT patients. 
Patients and methods

Patients
Objectives
The primary objective was to estimate the incidence of bleeding events and mortality rates in patients who had undergone HSCT and had experienced respiratory and/or cardiovascular organ dysfunction because of severe sepsis and/or GVHD. Severe bleeding events, especially intracranial hemorrhage (ICH), during 100 days following the date of meeting the entry criteria (MEC), as well as the 28-day and 100-day post-MEC mortality rates, were analyzed.
The secondary objectives comprised the evaluation of patient blood parameters such as hemoglobin levels, platelet, leukocytes and neutrophil counts.
Entry criteria and data collection
To obtain valid, consistent information from a predefined and homogeneous patient population, detailed entry criteria were rigidly defined prospectively. For every transplantation performed during the screening period (October 2001-March 2003), a screening page was compiled detailing the information in Table 1 . A documentation package was recorded, but only for patients who retrospectively met these entry criteria within a time frame of p180 days from HSCT.
Inclusion criteria
All three inclusion criteria (A, B and C) had to be met for eligible entry into the study. Sepsis was defined by proven or suspected infection, and GVHD by Glucksberg grades III/IV. 6 (c) Presence of cardiovascular and/or respiratory organ dysfunction. Cardiovascular organ dysfunction was defined by arterial systolic blood pressure p90 mm Hg or mean arterial pressure p70 mm Hg or the requirement for vasopressors. Respiratory organ dysfunction was defined by an oxygen saturation of p90% despite oxygen support (X4 l oxygen/min) or PaO 2 / FiO 2 p200.
Exclusion criteria
Patients were excluded from the study if at least one of the following factors was present: international normalized ratio (INR43) despite transfusion support; refractory to platelet transfusions; participation in any study involving administration of an investigational compound to treat any condition other than cancer within the last 30 days; increased risk of bleeding (including those who would be likely to experience serious bleeding events if given DAA; also in addition, a number of criteria aimed to exclude patients who were considered to be likely to die of their preexisting uncorrectable medical condition before completing the study, for example, recurrence of hematologic malignancy after current HSCT. Additional organ failures not valid for study entry were defined for the following:
Renal: average urine output o0.5 ml/kg/h for 1 h despite adequate fluid resuscitation, not valid in case of preexisting renal failure. Coagulation: increase in PT or PTT X2.0 times the upper limit of normal.
Unexplained metabolic acidosis defined as: pH p7.30 or base deficit X5.0 mEq/l and plasma lactate level 41.5 times the upper limit of normal for the reporting laboratory.
Definition of bleeding
Any bleeding event was reported that occurred within 28 days after MEC; only documentation of rare petechiae were excluded. A bleeding was considered serious if it resulted in one of the following outcomes or was significant for any other reason: fatal; prolonged inpatient hospitalization or rehospitalization; a life-threatening experience (that is, the patient was at immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect.
Transfusions
Transfusions were reported that occurred during the 28 days after MEC. One unit was defined as 500 IU antithrombin, or 200 IU PPSB or one bag of fresh-frozen plasma or platelets or packed RBCs.
Sample size
It was planned to include approximately 150 patients in this study. Assuming an ICH incidence rate for HSCT patients with severe sepsis of 2%, this sample size allowed an estimate of the ICH incidence rate with 95% CI to be within 0.41 and 5.48% using Poisson approximation. Assuming a 28-day mortality rate of 65%, a precision of ± 7.6% (95% normal approximation confidence interval) would be achieved. Therefore, the sample size was appropriate to estimate ICH incidence and mortality rates for HSCT patients with severe sepsis and/or GVHD.
Statistical analyses
All analyses were carried out using SAS version 8.2 based on patients MEC. Descriptive statistics were used to summarize the patients' characteristics. According to Pearson and Clopper, 95% CIs were used to describe mortality (patients lost to follow-up were considered dead after lost to follow-up, affecting one patient). To establish a threshold platelet count that predicts mortality and bleeding, Fisher's exact test together with odds ratios and their confidence intervals were used, dichotomizing the platelet count in steps of 1 Â 10 9 /l from 4 Â 10 9 to 30 Â 10 9 /l and at 50 Â 10 9 and 80 Â 10 9 /l. The lowest platelet count at which the risk of death or bleeding was not increased was used as the threshold, that is, for all lower counts, the risk of death or bleeding increased steadily.
All laboratory parameters were documented over a time period starting from 3 days before MEC to 28 days post-MEC. For evaluation, time periods were summarized to 4 'day categories': À3 to À1 days to MEC, day of MEC, 1-7 days after MEC, and 47 days post-MEC. The maximum value during this time period was analyzed for C reactive protein (CRP), activated partial thromboplastin time (aPTT) and INR, whereas the minimum value was analyzed for Quick. Table 2 ).
Results
Patient characteristics
The vast majority of patients received stem cell grafts for hematological malignancies. A very limited number (3.5%) were excluded from evaluation because of a non-hematological condition for transplantation. Not surprisingly, the absence of respiratory or cardiovascular organ dysfunction owing to sepsis and/or GVHD was the major reason for non-eligibility. Fewer than 5% of all screened patients met at least one of the pre-specified exclusion criteria as well as the three inclusion criteria. The main criteria for exclusion were increased risk of bleeding, presence of aspergillosis or known infection of the brain, recurrence of hematological malignancy and refractoriness to platelet transfusions. Of the 1932 patients not included in the study, 73 (3.8%) were excluded because of the indication of HSCT; for 1779 patients (92.1%), there was no respiratory or cardiovascular dysfunction because of sepsis or GVHD, and 95 patients (4.9%) had further unresolved exclusion criteria. Bleeding events and mortality in SCT patients E Holler et al
Criteria for study entry Sepsis was documented as the main reason for organ dysfunction in 96.9% of patients; five patients (3.1%) experienced organ dysfunction because of GVHD only without underlying sepsis. In 15.6% of patients, GVHD was considered as a reason. Sepsis combined with GVHD was therefore recorded in 20 patients (12.5%). Respiratory failure and cardiovascular organ dysfunction were documented at screening for 68.1 and 63.1% of all patients, respectively. Although one organ dysfunction was sufficient for study entry, 50 patients (31.3%) suffered from both respiratory and cardiovascular organ dysfunction at MEC. Renal coagulation and unexplained metabolic acidosis, although documented as additional organ failures, were not valid for study entry. Including the latter organ dysfunctions, 63.8% of the enrolled 160 patients experienced multiple organ dysfunctions at study entry ( Figure 1 ).
Mortality and cause of death
The 28-day all-cause mortality rate was 53.1% (n ¼ 85) (95% CI 45.1-61.0%) and the 100-day mortality rate was 65.6% (n ¼ 105; 95% CI 57.7-72.9%; Figure 2 ). For about half of the cases (49.5%), sepsis including multiple organ failure was documented as the cause of death; 15.2% of patients died of refractory septic shock. A total of 64.7% of cases were therefore documented to have died from sepsis. Of the patients 20% died of respiratory failure, 2.9% of GVHD and 2.9% of hemorrhages. For 9.5%, the unspecified reason 'other' was documented as the cause of death.
The mortality of patients with at least one documented bleeding event was higher compared with non-bleeders (28-day mortality 68.8% (95% CI 50.0-83.9%) vs 49.2% (95% CI 40.3-58.2%)). Similarly, a higher mortality rate was seen after allogenic transplantation compared with autologous (related 57.7% (95% CI 43.2-71.3%) and unrelated 61.0% (95% CI 49.2-72.0%) vs 26.7% (95% CI 12.3-45.9%)). The mortality rate almost doubled if the patient experienced more than one organ dysfunction at MEC (32.8% (95% CI 21.0-46.3%); 64.7% (95% CI 55.4-74.0%)).
Platelet count
Platelet counts were low during the entire observation period. Only about one-third (35.3%, 54 of 153) of the patients had platelet counts above 30 Â 10 9 /l on the day of MEC. In the following 7 days, 12.7% (19 of 160) continuously had platelet counts above this threshold.
During the bleeding events, the median minimum platelet count was found to be 12 Â 10 9 /l, and the median maximum count was only 27.5 Â 10 9 /l, ranging from 8 to 174 Â 10 9 /l. An analysis of the relationship between platelet count and mortality revealed a significantly increased risk of Bleeding events and mortality in SCT patients E Holler et al death in patients with platelets lower than 15 Â 10 9 /l (odds ratio ¼ 3.15 (95% CI 1.55-6.41), P ¼ 0.001, see Figure 3 ).
Bleeding complications
Overall, 63 bleeding events were documented (Table 3) . At least one bleeding event was experienced by 32 patients (28-and 100-day incidence 20% (95% CI 14.1-27.0%). One-quarter (8) of these 32 patients experienced only nonserious bleedings, whereas for 75% (24) at least one serious bleeding event was reported. One-fifth of all bleeding events were considered to have been life-threatening and an additional fifth fatal. The majority of these events affected either the lungs, GI tract or brain (fatal: GI tract 3, lung: 4, brain: 5; life-threatening: GI tract 7, lung: 1).
Five patients experienced an ICH, three of whom had a platelet count of less than 15 Â 10 9 /l (1 Â 10 9 , 6 Â 10 9 , 11 Â 10 9 /l) at MEC.
The analysis of the relationship between platelet count and bleeding revealed an increased risk of bleeding in patients with platelets lower than 13 Â 10 9 /l (odds ratio ¼ 3.54 (95% CI 1.57-7.95), P ¼ 0.003, see Figure 4 ).
The absence of significant differences in laboratory parameters aPTT, INR and Quick between patients with low platelets and patients with bleeding and non-bleeding events is worth noting.
Transfusions
A total of 2081 transfusions were documented for 93.1% of all patients; half (52.9%) were platelets, followed by packed RBCs (almost one-third). The most prevalent reason for platelet transfusion was low platelet counts without signs of bleeding (87.4%). Packed RBCs, 621 U, were transfused mainly because of low hemoglobin levels, without signs of bleeding (83.5%). Fresh-frozen plasma (260 U) was transfused for coagulation disorders in two-thirds of the cases. For the remaining one-third, the unspecified term 'other' was documented.
Leukocytes and neutrophils
Almost two-thirds of the patients presented with a leukocyte count of less than 1 Â 10 9 /l at MEC. This can be explained by the short time period between the date of transplantation and MEC; median time was 18 days, range 0-175 days. Neutrophil count was reported less frequently, with reports missing in around 40% for the day categories. About one-half of all patients with reported values had neutrophils below 0.5 Â 10 9 /l at MEC. patients with platelet count at MEC higher than the value on the horizontal axis, for example, mortality approximately 42% for patients with more than 24 000 platelets/mm 3 (24 Â 10 9 /l). Line shows P-value for mortality of these patients compared with all other patients, that is, those with a platelet count at MEC lower than the value on the horizontal axis.) Table 3 Bleeding events Laboratory parameters Maximum C-reactive protein values for patients with fatal outcome were found to be higher than in survivors ( Figure 5 ).
Discussion
Baseline characteristics of patients in the HISTORY study show no unexpected findings. The majority of patients were young with a median age of 44.15 years (range 19-65). Leukemia was the most prevalent underlying malignancy.
The conditioning regimens before HSCT were in line with the standard of care in Europe. Most patients received allogeneic SCTs. Peripheral blood was a source of hematopoietic cells in 80.6% of cases. As expected, corroborating earlier reports from the literature, this study confirmed high mortality rates: 53.1% within 28 days, and 65.6% within 100 days post-MEC in patients with severe sepsis and organ dysfunction following HSCT.
Septic shock with organ dysfunction, and GVHD, were recorded in 96.9 and 15.6% of patients, respectively (multiple specifications possible). Of the patients, 75.6% received at least one medication (mainly CsA and steroids) for treatment and/or prophylaxis of GVHD. In 64.7% of cases, sepsis was reported to be the direct cause of death. Respiratory failure was considered to be the cause of fatal outcome in 20%. If we postulate that respiratory failure could be attributed to sepsis as well, then sepsis would account for about 84% of deaths. Hemorrhage was the direct cause of mortality in 2.8% of patients.
In 70.6% of patients, blood counts were still low because of aplasia following pretransplant conditioning. However, even after engraftment, immunocompromised patients were commonly recorded to have low platelet counts throughout the entire observation period, especially up to day 7 post-MEC. Only one-third of patients had platelet counts X30 Â 10 9 /l at MEC. Persistence of low platelet counts or secondary drops in platelet counts may be observed over weeks or months 7, 8 following HSCT, and other multiple Bleeding events and mortality in SCT patients E Holler et al causes, including myelosuppression by GVHD or increased consumption of platelets by endothelial activation or post transplant microangiopathy, have been reported. The incidence of bleeding was within the expected range: 20% of patients (32 of 160) experienced a total of 63 bleeding events (severity not considered and patients at increased risk of bleeding were excluded as detailed in Patients and methods). 7, 9 In all cases, time to first bleeding event was within 28 days post-MEC, thus near to HSCT for the majority of patients.
Patients with platelets below 13 Â 10 9 /l experienced more bleeding events than patients with higher counts (P ¼ 0.003). Apart from the correlation of increased bleeding risk with low platelet counts, a clear relationship was then established between higher bleeding event rates at the lower platelet counts and subsequent mortality. Patients with platelets below 15 Â 10 9 /l at MEC had an increased risk of death compared with patients with higher counts (P ¼ 0.001). Most patients (93.1%) received at least one transfusion, administered on a median number of 7 days. These were mainly platelet transfusions (52.9%) followed by packed RBCs (29.8%), given as bleeding prophylaxis.
In summary, patients who have undergone HSCT and who develop sepsis and/or GVHD despite the best standard of care still experience a high mortality. It has been shown that mortality in patients with sepsis and multiple organ dysfunction may be reduced by 20% after treatment with DAA. 5 However, treatment options for severe sepsis such as DAA are contraindicated in patients with severe thrombocytopenia. Whether patients identified in this retrospective study could potentially benefit from such intervention is unknown, as SCT patients were excluded in the trial PROWESS to avoid any increased risk of bleeding. The perception then was that HSCT together with other transplant patients had a high, potentially unmodifiable mortality from severe sepsis, which the results of this study disprove to some extent. Further evaluations through prospective clinical trials would be necessary to particularly assess the safety and efficacy of DAA in this patient population.
